

**S3 Table.** Pathoclinical profiles of the 95 patients whose tissue samples underwent immunohistochemical analysis

<b>Factor</b>	<b>Resistant group (n=55)</b>	<b>Sensitive group (n=40)</b>	<b>Chi-square</b>	<b>p-value</b>
<b>Sex</b>				
Male	33 (60.0)	28 (70.0)	1.008	0.315
Female	22 (40.0)	12 (30.0)		
<b>Age (yr)</b>				
≥ 55	31 (56.4)	17 (42.5)	1.781	0.182
< 55	24 (43.6)	23 (57.5)		
<b>Differentiation</b>				
Well- moderately	53 (96.4)	35 (87.5)	2.666	0.103
Poorly	2 (3.6)	5 (12.5)		
<b>T stage</b>				
T3	31 (56.4)	26 (65.0)	0.720	0.396
T4	24 (43.4)	14 (35.0)		
<b>N stage</b>				
N-	47 (85.5)	28 (70.0)	3.328	0.068
N+	8 (14.5)	12 (30.0)		
<b>CCT regimen</b>				
CAPEOX, 4 cycles	33 (60.0)	31 (77.5)	3.226	0.072
CAPEOX, 2 cycles	22 (40.0)	9 (22.5)		
<b>CCR6 level</b>				
High	42 (76.3)	15 (37.5)	14.574	< 0.001
Low	13 (23.7)	25 (62.5)		

Values are presented as number (%). The radiotherapy of the patients was all done with a technique of intensity-modulated radiotherapy and a dose of 50 Gy in 25 fractions. CCT, concurrent chemotherapy; CAPEOX, capecitabine plus oxaliplatin; CCR6, C-C motif chemokine receptor 6.